ENZ:NYE-Enzo Biochem Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 1.11

Change

-0.01 (-0.89)%

Market Cap

USD 0.06B

Volume

0.05M

Analyst Target

USD 5.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

-0.57 (-0.21%)

USD 199.35B
IQV IQVIA Holdings Inc

+2.69 (+1.12%)

USD 43.52B
A Agilent Technologies Inc

+0.66 (+0.48%)

USD 39.94B
LH Laboratory Corporation of Amer..

+0.21 (+0.09%)

USD 18.96B
DGX Quest Diagnostics Incorporated

+0.10 (+0.06%)

USD 17.18B
CRL Charles River Laboratories

-0.11 (-0.05%)

USD 10.65B
QGEN Qiagen NV

+0.02 (+0.04%)

USD 10.30B
VNRX Volitionrx Ltd

-0.05 (-7.58%)

USD 0.06B
TMO Thermo Fisher Scientific Inc

-0.37 (-0.06%)

N/A
MTD Mettler-Toledo International I..

+19.22 (+1.39%)

N/A

ETFs Containing ENZ

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.14% 8% B- 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.14% 8% B- 9% A-
Trailing 12 Months  
Capital Gain -20.14% 15% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.14% 15% F 9% A-
Trailing 5 Years  
Capital Gain -68.38% 17% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.38% 17% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain -10.79% 15% F 7% C-
Dividend Return -10.79% 15% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.60% 15% F 27% F
Risk Adjusted Return -30.30% 15% F 11% F
Market Capitalization 0.06B 11% F 21% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector